BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 18697418)

  • 1. [In vitro activity of tigecycline against multiple resistant Acinetobacter baumannii and carbapenem resistant Klebsiella pneumoniae isolates].
    Arikan Akan O; Uysal S
    Mikrobiyol Bul; 2008 Apr; 42(2):209-15. PubMed ID: 18697418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro tigecycline and carbapenem susceptibilities of clinical Acinetobacter baumannii isolates].
    Nayman Alpat S; Aybey AD; Akşit F; Ozgüneş I; Kiremitçi A; Usluer G
    Mikrobiyol Bul; 2010 Oct; 44(4):641-5. PubMed ID: 21063976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.
    Mezzatesta ML; Caio C; Gona F; Cormaci R; Salerno I; Zingali T; Denaro C; Gennaro M; Quattrone C; Stefani S
    Int J Antimicrob Agents; 2014 Aug; 44(2):112-6. PubMed ID: 25059444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro Activity of Colistin in Combination with Tigecycline against Carbapenem-Resistant Acinetobacter baumannii Strains Isolated from Patients with Ventilator-Associated Pneumonia.
    Cikman A; Gulhan B; Aydin M; Ceylan MR; Parlak M; Karakecili F; Karagoz A
    Int J Med Sci; 2015; 12(9):695-700. PubMed ID: 26392806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Over expression of AdeABC and AcrAB-TolC efflux systems confers tigecycline resistance in clinical isolates of Acinetobacter baumannii and Klebsiella pneumoniae.
    Yuhan Y; Ziyun Y; Yongbo Z; Fuqiang L; Qinghua Z
    Rev Soc Bras Med Trop; 2016 Apr; 49(2):165-71. PubMed ID: 27192584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in the susceptibility of clinically important resistant bacteria to tigecycline: results from the Tigecycline In Vitro Surveillance in Taiwan study, 2006 to 2010.
    Chen YH; Lu PL; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Liu JW; Sun W; Wang LS; Ko WC; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1452-7. PubMed ID: 22203598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010.
    Fernández-Canigia L; Dowzicky MJ
    Ann Clin Microbiol Antimicrob; 2012 Oct; 11():29. PubMed ID: 23088592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
    Karaoglan I; Zer Y; Bosnak VK; Mete AO; Namiduru M
    J Int Med Res; 2013 Dec; 41(6):1830-7. PubMed ID: 24265334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of TP-6076 against carbapenem-resistant Acinetobacter baumannii isolates collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Voulgaris GL; Papanikolaou G; Legakis N;
    Int J Antimicrob Agents; 2018 Aug; 52(2):269-271. PubMed ID: 29559273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minocycline and Tigecycline: What Is Their Role in the Treatment of Carbapenem-Resistant Gram-Negative Organisms?
    Shankar C; Nabarro LEB; Anandan S; Veeraraghavan B
    Microb Drug Resist; 2017 Jun; 23(4):437-446. PubMed ID: 27564414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Containment of carbapenem resistance rates of Klebsiella pneumoniae and Acinetobacter baumannii in a Greek hospital with a concomitant increase in colistin, gentamicin and tigecycline resistance.
    Meletis G; Oustas E; Botziori C; Kakasi E; Koteli A
    New Microbiol; 2015 Jul; 38(3):417-21. PubMed ID: 26147150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Agreement assessment of tigecycline susceptibilities determined by the disk diffusion and broth microdilution methods among commonly encountered resistant bacterial isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2008 to 2010.
    Liu JW; Ko WC; Huang CH; Liao CH; Lu CT; Chuang YC; Tsao SM; Chen YS; Liu YC; Chen WY; Jang TN; Lin HC; Chen CM; Shi ZY; Pan SC; Yang JL; Kung HC; Liu CE; Cheng YJ; Chen YH; Lu PL; Sun W; Wang LS; Yu KW; Chiang PC; Lee MH; Lee CM; Hsu GJ; Hsueh PR
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1414-7. PubMed ID: 22155819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial-resistant Pseudomonas aeruginosa and Acinetobacter baumannii From Patients With Hospital-acquired or Ventilator-associated Pneumonia in Vietnam.
    Biedenbach DJ; Giao PT; Hung Van P; Su Minh Tuyet N; Thi Thanh Nga T; Phuong DM; Vu Trung N; Badal RE
    Clin Ther; 2016 Sep; 38(9):2098-105. PubMed ID: 27612610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility of extended-spectrum beta-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial.
    Hoban DJ; Bouchillon SK; Dowzicky MJ
    Diagn Microbiol Infect Dis; 2007 Apr; 57(4):423-8. PubMed ID: 17403448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016).
    Pfaller MA; Huband MD; Streit JM; Flamm RK; Sader HS
    Int J Antimicrob Agents; 2018 Jun; 51(6):848-853. PubMed ID: 29410368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of tigecycline against clinical isolates of carbapenem resistant Acinetobacter baumannii complex in Pretoria, South Africa.
    Ahmed NH; Baba K; Clay C; Lekalakala R; Hoosen AA
    BMC Res Notes; 2012 May; 5():215. PubMed ID: 22554305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EVALUATION OF IN VITRO TIGECYCLINE ACTIVITY AGAINST MULTIDRUG-RESISTANT ACINETOBACTER BAUMANNII CLINICAL ISOLATES FROM POLAND.
    Paluchowska P; Nowak P; Skalkowska M; Bjdak A
    Acta Pol Pharm; 2017 May; 74(3):793-800. PubMed ID: 29513948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity of cefiderocol (S-649266) against carbapenem-resistant Gram-negative bacteria collected from inpatients in Greek hospitals.
    Falagas ME; Skalidis T; Vardakas KZ; Legakis NJ;
    J Antimicrob Chemother; 2017 Jun; 72(6):1704-1708. PubMed ID: 28369471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy.
    Mezzatesta ML; Trovato G; Gona F; Nicolosi VM; Nicolosi D; Carattoli A; Fadda G; Nicoletti G; Stefani S
    Ann Clin Microbiol Antimicrob; 2008 Feb; 7():4. PubMed ID: 18261233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan.
    Liu JW; Wang LS; Cheng YJ; Hsu GJ; Lu PL; Liu YC; Chen CM; Lee CM; Sun W; Jang TN; Chiang PC; Chuang YC; Lin HC; Shi ZY; Kung HC; Huang CH; Tsao SM; Lu CT; Liao CH; Hsueh PR
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 3():S188-91. PubMed ID: 19013353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.